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Abstract: Historically, mice and guinea pigs have been the rodent models of choice for 
therapeutic and prophylactic countermeasure testing against Ebola  virus disease (EVD). 
Recently, hamsters have emerged as a novel animal model for the in vivo study of EVD. In 
this review, we discuss the history of the hamster as a research laboratory animal, as well 
as current benefits and challenges of this model. Availability of immunological reagents is 
addressed.  Salient  features  of  EVD  in  hamsters,  including  relevant  pathology  and 
coagulation parameters, are compared directly with the mouse, guinea pig and nonhuman 
primate models.  
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1. Introduction 
Ebola virus (EBOV), a member of the family  Filoviridae, is the etiologic agent of Ebola virus 
disease (EVD), a severe hemorrhagic fever syndrome with unusually high case-fatality rates, ranging 
between  65–90%.  Filoviruses  are  emerging/reemerging  zoonotic  agents  that  are  highly  virulent  in 
primates, and the frequency of outbreaks in Africa and Asia and impact on ape populations have been 
increasing in recent years. Introduction of filoviruses into human populations leads to serious, albeit 
limited, epidemics. Interhuman transmission occurs by direct person-to-person contact and possibly by 
fomites  and  droplets.  Filoviruses  infect,  among  others,  monocytes,  macrophages,  dendritic  cells, 
hepatocytes, and endothelial cells. In the infected primate, these viral infections lead to severe cytokine 
imbalances  that  impair  the  innate  and  adaptive  immune  responses,  disseminated  intravascular 
coagulation (e.g., hemorrhages, thrombi), and organ necroses that result in  multi-organ failure and 
shock. No approved vaccines or effective therapeutics are currently available. Because of the high 
case-fatality rates of EVD and the lack of an approved vaccine or therapy, EBOV is classified as a 
category A pathogen requiring biosafety level-4 (BSL-4) biocontainment.  
2. Ebola Virus Disease (Humans): Clinical Presentation and Pathogenesis 
Ebolaviruses likely enter the body via direct contact (skin abrasions, mucous membranes) or contact 
with bodily fluids to directly access the vascular system or indirectly access the lymphatic system [1]. 
Limited human data indicate that monocytes/macrophages and dendritic cells are primary sites of virus 
replication [2]. Ebolaviruses spread from initial infection sites via macrophages and dendritic cells 
trafficking to regional lymph nodes, liver, and spleen [1]. After an incubation period of 4–16 days, 
patients initially present with influenza-like symptoms such as abdominal pain, anorexia, arthralgia, 
asthenia,  back  pain,  diarrhea,  fever,  headaches,  enlarged  lymph  nodes,  myalgia,  nausea,  or  
vomiting [3–5]. After approximately 5–7 days, a maculopapular rash usually develops on the face, 
buttocks, trunk, or arms and later generalizes over almost the entire body. As EVD progresses, more 
severe and multisystem symptoms include respiratory (e.g., chest pain, terminal tachypnea, cough), 
vascular (e.g., conjunctival injection, postural hypotension, disseminated intravascular coagulation), 
urinary (e.g., anuria), and neurologic (e.g., headache, confusion, coma) manifestations [5,6]. In fatal 
EVD cases, hemorrhagic manifestations are usually striking with hematemesis, hemoptysis, melena, 
hematuria,  epistaxis,  and/or  widespread  petechiae  and  ecchymoses  involving  skin,  mucous 
membranes,  and  internal  organs  [7,8].  Hemorrhagic  manifestations  occur  approximately  3–4  days 
postonset  of  influenza-like  symptoms  and  progress,  in  fatal  cases,  to  disseminated  intravascular 
coagulation  (decrease  of  clotting  factors, thrombocytopenia,  increased  fibrin  degradation  products, 
prolonged thrombin and activated partial thromboplastin times) [5,9,10].  
Death  occurs  3–21  days  after  disease  onset  from  shock  after  multi-organ  failure  (liver,  spleen, 
kidney). Liver damage is characterized by hepatocellular necrosis, sinusoidal dilation and congestion 
(hepatomegaly),  and  elevated  concentrations  of  aspartate  transaminase  (AST),  alanine 
aminotransferase  (ALT),  alkaline  phosphatase  (ALP),  and  γ-glutamyl  transferase  (GGT)  [2–4,10]. 
Within the spleen, marked hyperemia and splenomegaly, cellular depletion of the red pulp, and/or 
marked atrophy of the lymphoid follicles are observed [8,11]. Lymphoid hypoplasia or depletion has Viruses 2012, 4  3756 
 
been noted in patients with EVD [2,8,11]. Leukopenia (lymphopenia) and granulocytosis are present 
initially in patients with EVD, and as the disease progresses, leukocytosis results from an increase in 
immature  granulocytes  and  atypical  lymphocytes  [4,12,13].  Acute  renal  tubular  necrosis  and 
calcification  of  renal  tubules  and  glomerular  tufts  are  noted  [2,3,14].  Creatinine  and  urea 
concentrations  increase  prior  to  renal  failure,  and  hypokalemia  is  typical  due  to  diarrhea  and/or 
vomiting.  Lung  hemorrhage  (hemoptysis)  progresses  to  focal  atelectasis  and  is  accompanied  by 
interstitial pneumonitis [2,11]. 
Infected monocytes/macrophages release soluble mediators including proinflammatory cytokines 
and vasoactive substances [15]. These cytokines recruit additional macrophages to infected areas and 
could increase the number of target cells available for virus infection, further amplifying an already 
dysregulated host response [16]. EBOV-infected patients with  a  fatal outcome  exhibited  increased 
concentrations  of  interferon  (IFN)-γ,  IFN-α,  interleukin  (IL)-2,  IL-6,  IL-8,  IL-10,  IL-1  receptor 
antagonist,  macrophage  inflammatory  protein-1β,  neopterin,  or  tumor  necrosis  factor  (TNF)-α, 
although differences in cytokine release were apparent between variants of EBOV [15,17,18].  
3. Existing Animal Models of EVD 
The  development  of  animal  models  that  accurately  reflect  human  disease  is  critical  to  our 
understanding  of  the  pathogenesis  of  EVD  and  evaluation  of  countermeasures  against  filoviruses. 
Because of the sporadic and geographically isolated nature of EVD outbreaks, clinical efficacy studies 
may not be feasible. Clinical data and access to human tissues from fatal cases are limited.  
Another option for licensing new drugs and vaccines for EVD is extrapolation of data derived from 
accurate, validated animal models supported by human safety evaluation data and pharmacokinetic 
information. The “Animal Rule” from the U.S. Food and Drug Administration [19] requires that a 
countermeasure be evaluated in animal models in which the route and dose of virus administration, 
time to onset of disease, and time course/progression of disease optimally mimic the pathophysiology 
of human disease. One of the challenges with this regulatory pathway is the development of animal 
models that recapitulate human disease, as data on the clinical presentation of EVD disease in humans 
are quite limited.  
The  nonhuman  primate  (NHP)  model  of  EVD  is  the  gold-standard  for  the  study  of  EVD 
pathogenesis that most closely resembles what we currently know regarding human disease. Guinea 
pigs and mice are regarded as models for preliminary evaluation of therapeutic interventions against 
EVD. As wild-type EBOV does not produce appreciable disease in these rodent models, EBOV was 
adapted by serial passage to produce fatal infection following intraperitoneal (IP) inoculation [20,21]. 
The pathogenesis of EVD from adapted rodent viruses differs in a number of aspects from EVD in 
humans  and  NHPs.  Important  clinical  signs  of  EVD  in  humans  and  NHPs  such  as  fever  and 
maculopapular  rash  are  not  present  in  mice  infected  with  mouse-adapted  Ebola  virus  
(MA-EBOV) [20,22]. Fever is present in guinea pigs infected with guinea pig-adapted Ebola virus 
(GPA-EBOV), but maculopapular rash does not develop in these animals [21]. Mice infected with 
MA-EBOV do not consistently display coagulation abnormalities (Table 1) [20,23,24]. Compared to 
mice, guinea pigs infected with GPA-EBOV develop coagulation defects, including a drop in platelet Viruses 2012, 4  3757 
 
counts and an increase in coagulation time, but fibrin deposition and coagulopathy (i.e., disseminated 
intravascular coagulation) are not as marked as that observed in NHPs [21,25].  
Table 1. Coagulation parameters in animal models of Ebola virus disease 
a. 
Coagulation Parameter 
Rhesus 
Macaque 
b 
Syrian 
Hamster 
c 
Guinea Pig 
d  Mouse 
c 
Increased prothrombin time (PT)  (++) [26,27]  (+++)  (+++)  (-) [20,27]
 
Increased activated partial 
thromboplastin time (aPTT) 
(++) [26,27]  (+++)  (++)  (-)[20,27] 
Increased thrombin time (TT)  (++) [26,27]  (++)  ND  ND 
Late hypofibrinogenemia  (+++) [26,27]  (++) 
(-) (increased 
fibrinogen) 
(-/+) [20,27] 
Decreased protein C activity %  (+++) [26,27]  (+++)  ND  ND 
Thrombocytopenia  (++) [26,27]  (++) 
(++) 
e [20] / 
(+++) 
f [21] 
(++) [20,28] 
 
a: From Ebihara [27], unless otherwise noted 
b:
 Infected with wild-type EBOV  
c:
 Infected with MA-EBOV 
d:
 Hartley guinea pigs infected with GPA-EBOV, unless otherwise noted 
e: Inbred strain 2 United States Army Medical Research Institute for Infectious Diseases (USAMRIID) guinea pig  
colony infected with MA-EBOV 
f: Inbred strain 13 USAMRIID guinea pig colony infected with GPA-EBOV 
ND: no data 
 
Further, bystander lymphocyte apoptosis, an important feature in primates and mice, has not been 
determined  in  guinea  pigs  infected  with  GPA-EBOV.  Mice  infected  with  MA-EBOV  differ  from 
guinea  pigs  infected  with  GPA-EBOV  and  monkeys  infected  with  wild-type  EBOV  in  that  they 
display  a  decrease  in  blood  urea  nitrogen  (BUN),  rather  than  an  increase  [20].  Because  of  these 
differences  in  EVD  in  rodent  models,  a  number  of  therapeutic  interventions  that  are  effective  in 
rodents challenged with adapted EBOV fail to protect NHPs challenged with wild-type EBOV from 
EVD  (Tables  2–3,  see  Supplemental  Tables  1–2  for  unabridged  versions).  Of  the  five  equivalent 
vaccines tested in rodents and NHPs with a comparable degree of immunocompetence, two vaccines 
had equivalent protection in all animal models tested, and three vaccines that provided some protection 
in rodents were not protective in NHPs. In evaluation of peri-exposure treatment of EVD, vesicular 
stomatitis virus (VSV) viral vectors provided roughly the same percentage of protection in guinea pigs 
and NHPs. Transfer of  immune serum or equivalent polyclonal or monoclonal  antibodies to naïve 
infected animals provided no protection to NHPs and some protection to rodents. Administration of 
equivalent  antisense  phosphorodiamidate  morpholino  oligomers  to  NHPs  provided  less  protection 
against EVD than rodents.  Viruses 2012, 4  3758 
 
Table 2. Efficacy of vaccines in animal models of Ebola virus disease. 
Vaccines  Immunization Schedule  Mouse Model  Guinea Pig Model  NHP Model 
Virus Vectors 
HPIV3 Immunogens 
 EBOV GP [29–31]  
 EBOV NP [31] 
 EBOV GP + NP [30] 
Guinea Pigs:  
 IN 4 × 10
6 PFU of HPIV3/EBOV 
GP [29]  
 IN 10
5.3 PFU of HPIV/EBOV GP 
or NP [31] 
HPIV3- NHPs:  
 IN plus IT 4 × 10
6 TCID50 of 
HPIV3/EBOV GP, 
HPIV3/EBOVGP+NP or 2 × 10
7 
TCID50 of HPIV3/EBOV GP-1–2 
doses [30]  
    Complete protection with 
HPIV3/EBOV GP or 
HPIV/EBOV NP [29,31] 
  Strong humoral response 
 Complete protection with 
2 doses of HPIV3/EBOV 
GP [30] 
 No advantage to bivalent 
vaccines 
VSV ∆GP Immunogens 
EBOV GP attenuated 
[32–38]  
 
 
 
 
 
 
Immunocompetent Mice:  
 IP, IM, IN, PO 1–2 × 10
4 PFU of 
VSV∆GP/EBOV GP [32,33,35]  
 IP 2–2 × 10
3 PFU [35] 
NOD-SCID Mice: IP 2 × 10
5 PFU 
of VSV∆GP/EBOV GP 
Guinea Pigs: IP 2 × 10
5 PFU-1–2 
doses of VSV∆GP/EBOV GP 
[32] 
HIV + NHPs: IM 1 × 10
7 PFU [34] 
Immunocompetent NHPs: 
 IM 1 × 10
7 PFU of 
VSV∆GP/EBOV GP [38] 
 PO, [36] IN, [36] IM [36,37] 2 × 
10
7 PFU of VSV∆GP/EBOV GP  
 Complete protection in NOD-SCID 
mice with high-dose 
VSV∆GP/EBOV GP [35] 
 Complete protection with 
VSV∆G/EBOV GP live vector in 
immuncompetent mice [32,33,35] 
regardless of route of 
administration [35] 
 Complete protection with 
VSV∆G/EBOV GP given 7 days 
prior to challenge  
 
 
 Complete protection with 
VSV ∆GP/EBOV GP [32] 
 
 67% protection with VSV 
∆GP/EBOV GP in HIV+ 
NHPs mediated by CD4+ 
cells [34] 
 Complete protection with 
VSV ∆GP/EBOV GP  
[36–38] in 
immunocompetent NHPs 
regardless of route of 
vaccination 
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Table 2. Cont. 
Vaccines  Immunization Schedule  Mouse Model  Guinea Pig Model  NHP Model 
Virus Vectors 
VV Immunogens 
 EBOV GP [24,39] 
 
Guinea Pigs: SC 10
7 of VV/EBOV 
GP–3 doses [39] 
NHPs: SC of VV/EBOV GP–3 
doses [24] 
   60% protection with 
VV/EBOV GP [39] 
 Survival correlated with 
neutralizing antibodies 
 No protection with VV/ 
EBOV GP [24] 
 Viremia present in all 
subjects 
Virus-like Particles (VLPs)  
VEEV RNA (VRP) encoding: 
 EBOV NP [24,40–42] 
 EBOV GP [24,41–44] 
 EBOV GP+NP [24,41] 
EBOV VP24, VP30, VP35, or 
VP40 [42,45] 
Mice:  
 SC 2 x 10
6 FFU of VRP/EBOV 
NP– 3 doses [40] 
 SC 2 × 10
6 FFU or 2 × 10
6 IU of 
VRP/EBOV NP, VP24, VP30, 
VP35, or VP40 for 2–3 doses 
[42,45] 
 SC 1 × 10
6IU of VRP/EBOV GP 
or NP or GP + NP–2  
doses [41] 
 SC 1 × 10
8 of VRP EBOV GP–4 
doses [43] 
Guinea Pigs: SC 10
7 IU of VRP 
EBOV GP, NP, or GP+NP–2 or 3 
doses [41,44] 
NHPs: SC 2 x 10
6 FFU of VRP 
EBOV GP, NP or GP+NP–3 
doses [24] 
  75–100% protection with 
VRP/EBOV NP [40–42] 
  90–100% protection with 
VRP/EBOV GP [41–43] 
  Complete protection with 
VRP/EBOV GP+NP [41]  
  95–100% protection with 
VRP/EBOV VP proteins in 
BALB/c mice [42]  
  100% protection with 
VRP/EBOV VP 30 or VP 35 
proteins in C57BL/6 mice [42] 
  80% protection with VRP/EBOV 
VP40 in C57BL/6 mice [42] 
  No protection with VRP/EBOV 
VP24 protein in C57BL/6 mice 
[42,45] 
 Strain 2 guinea pigs (2 doses): 
no protection with VRP/EBOV 
NP; 60% protection with VRP-
EBOV GP [41] 
 Strain 13 guinea pigs (3 doses): 
complete protection with VRP-
EBOV GP; 20% protection 
with VRP/EBOV NP 
  100% protection with 
VRP/EBOV GP [44] 
 No protection with 
VRP/EBOV GP or NP or 
both immunogens [24] 
 Viremia present in all 
subjects 
 Time to death similar to 
controls 
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Table 2. Cont. 
Vaccines  Immunization Schedule  Mouse Model  Guinea Pig Model  NHP Model 
Ebola Virus Vaccines 
EBOV  
 Live [20,22,46,47] 
 irradiated [24,48,49] 
 irradiated, in liposomes  
[24,49] 
 INA+ UV irradiated, MA [50] 
 
Mice 
 SC, IM, ID 100 PFU MA-EBOV 
prior to IP challenge 
[20,22,46,47] 
 IP 10 µg of irradiated EBOV–3 
doses [48] 
 IM, IV 1.4 µg of irradiated 
EBOV alone or in liposome–2 
doses [49] 
 IM 5 × 10
4 PFU of INA 
inactivated MA-EBOV–1 or 2 
doses [50] 
NHPs: 
 IV 194 µg of EBOV 
encapsulated in liposome–3  
doses [49] 
 SC 50 µg of irradiated EBOV–3 
doses [24] 
 Complete protection with SC, IM 
live EBOV; [20,22,46] protection 
dependent on CD8+ cells and 
interferon-α/β receptors and not on 
B or CD4+ cells [20,47] 
 Persistent infection in CD4-
depleted or B cell-deficient  
mice [47] 
 Complete protection with IV 
irradiated liposome encapsulated 
EBOV [49] 
 77% protection with IM liposome 
encapsulated EBOV  
 25, 45, or 55% protection with IP-, 
IM-, or IV-irradiated EBOV, 
respectively [48,49] 
 >80% protection with INA-
inactivated EBOV [50] 
    No protection with 
liposome encapsulated 
EBOV; viremia [49] 
  25% protection with 
irradiated EBOV; viremia 
present in all  
macaques [24]  
  Neutralizing antibody 
titers present in 1 
surviving macaque 
immunized with 
irradiated EBOV  
Abbreviations:  EBOV:  Zaire  ebolavirus  species;  FFU:  focus-forming  units;  GP:  glycoprotein;  HIV:  human  immunodeficiency  virus;  GPA:  guinea  pig  adapted;  
HPIV3:  human  parainfluenza  virus  type  3;  IM:  intramuscular;  IN:  intranasal;  INA:  1,5-iodonaphthylazide;  IP:  intraperitoneal;  IT:  intratracheal;  IV:  intravenous;  
MA:  mouse  adapted;  NHP:  nonhuman  primate;  NOD:  nonobese  diabetic;  NP:  nucleoprotein;  PFU:  plaque-forming  units;  PO:  oral;  RNA:  ribonucleic  acid;  
SC:  subcutaneous;  SCID:  severe  combined  immunodeficiency;  TCID:  tissue  culture  infective  dose;  VEEV:  Venezuelan  equine  encephalitis  virus;  VLP:  virus-like  particles;  
VP: viral protein; VRPs: VEEV RNA replicon particles; VSV: vesicular stomatitis virus: VV: vaccinia virus 
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Table 3. Efficacy of peri-exposure treatment in animal models of Ebola virus disease. 
Peri- exposure Treatment  Dose and Route of 
Administration 
Mouse Model  Guinea Pig Model  NHP Model 
Virus Vectors 
VSV ∆GP Immunogens 
 EBOV GP [51]  
 
Mice: IP 2 x 10
5 VSV 
∆GP/EBOV GP PFU -1 day 
before or +30 minutes or +1 
day after challenge [51] 
Guinea pigs: IP 2 x 10
5 VSV 
∆GP/EBOV GP PFU -24 
hours or +1 or 24 hours [51] 
NHPs: IM 2 x 10
7 PFU of VSV 
∆GP/EBOV GP [51] +20–30 
minutes  
 Complete protection with VSV 
∆GP/EBOV GP regardless of 
time of treatment [51] 
 Mild weight loss on + 1 day, 
suggesting viral replication  
 66, 83, or 50% protection with 
VSV ∆GP/EBOV GP -24 or +1 
or 24 hours, respectively [51]  
 50% protection with VSV 
∆GP/EBOV GP +20–30 
minutes [51] 
Passive Immunity 
Pooled immune serum to 
live EBOV [46,52] 
 
Mice: IP 1 mL of antisera (anti-
EBOV IgG titers of ≥6,400) -
1 day or + 1 day [46] 
NHPs: IV 6 mL/kg whole blood 
immediately after challenge 
and +3 or 4 days (anti-EBOV 
IgG ELISA titers of 100,000) 
[52] 
 89% protection with 
pretreatment with immune 
serum [46] 
 Complete protection with 
postchallenge treatment with 
immune serum  
 Protection correlated with anti-
EBOV IgG titers 
   No protection or delay in 
death with immune serum 
compared to controls [52] 
 Rapid decline of anti-
EBOV IgG titers by day 
+3  
 Comparable viremia in 
treated and control NHPs 
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Table 3. Cont. 
Peri- exposure Treatment  Dose and Route of 
Administration 
Mouse Model  Guinea Pig Model  NHP Model 
Passive Immunity 
Purified polyclonal IgG 
antibody against: 
 Unknown, EBOV-
immunized horses  
[53,54] 
 
Mice:  
 SC 0.03, 0.3, 3 mL/kg horse 
IgG (log serum neutralization 
index of 4.2) +20–30 minutes 
[54] 
Guinea Pigs: IM 1 mL/kg of 
horse IgG + several minutes 
and +3 days, or +4 days only 
[54] 
NHPs:  
 IM ~1 mL/kg of horse IgG -2 
days or day 0 [53,54], or day 
0 and day +5 [54] 
 25% protection with horse IgG 
at highest dose only; lower 
doses not effective [54] 
 
 Complete protection with horse 
IgG given at day 0 only; no 
viremia detected [54] 
 Complete protection with horse 
IgG with second dose at day 
+3; viremia not detected  
 No protection if IgG is delayed 
until day +4; transient 
reduction in viremia and anti-
EBOV titers not detected  
  
 No protection with horse 
IgG immediately 
postchallenge [53,54] or -2 
days [54] 
 Delayed viremia with 
reduction in anti-EBOV 
titers with NHPs receiving 
IgG immediately after 
challenge; no delay in death 
 33% protection with 2 doses 
of horse IgG 
 
mAb EBOV GP-specific 
 Human IgG1 [55,56] 
 
 
 
Guinea Pigs:  
 IP 0.5, 5, 50 mg/kg +several 
minutes [55] 
 IP 25 mg/kg -1 hour, or +1 
or 6 hours  
NHPs: IV 50 mg/kg -1 day and 
+4 days [56] 
   No protection when human 
mAb given +6 hours [55] 
 100% protection at highest 
dose (50 mg/kg) when human 
mAb given at time of challenge 
or -1 hour (25 mg/kg) 
 80% protection if human mAb 
given +1 hour 
 No protection with human 
mAb [56] 
 Minimal effect on EBOV 
viral replication  
 Cellular immunity may be 
needed for protection 
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Table 3. Cont. 
Peri- exposure Treatment  Dose and Route of 
Administration 
Mouse Model  Guinea Pig Model  NHP Model 
Antiviral Agents 
Antisense 
Phosphorodiamidate 
morpholino oligomers 
(PMO) [57–60]  
 
 
 
 
 
 
 
 
 
 
 
 
 
Mice: 
 IP 5, [58] 50, [58] or 500 
[57,58] µg of PMO targeting 
VP35 at -1 day and -4 hours  
 IP 1, 5, or 50 [58,60] or 500 
µg [60] of 3 PMOs targeting 
VP24, VP35, or L -4 hours or 
+1 day [58,60] 
  IP 10 mg/kg of PMO with 
piperazine moieties targeting 
VP24 and VP35 -1 day or 
+1–4 days [59] 
Guinea Pigs: IP 10 mg of each 
PMO targeting VP24, VP35 
or L -1 day or +1 or 6 days 
after challenge [58] 
 
 Complete protection with 
highest dose of 3 PMOs each 
targeting VP24,VP35, or L 
either pre- or postexposure 
[58] 
 Complete protection following 
pretreatment with 500 µg (2 
doses) of PMO targeting VP35 
[57,58]  
 Complete protection following 
pretreatment with PMOs 
targeting VP24 and VP35 
[58,59]  
 Postexposure protection 
diminishes with delay of 
administration of piperazine-
enriched PMOs targeting 
VP24 and VP35 [59] 
 <75% protection with 
combination of PMOs each 
targeting VP24, VP35, or L 
given +6 days [58] 
 <50% protection with 
combination PMOs given +1 
day  
 <25% protection with 
combination PMOs given -1 
day 
 Reduction in viral titer 
correlated with survival 
 50% protection with PMOs 
each targeting VP24, VP35, 
or L [58] 
 High anti-EBOV antibodies 
and T cell responses in 
survivors 
 No protection with PMO 
targeting VP35 only 
 62.5% protection with SC 
and IP piperazine-enriched 
PMOs targeting VP24 and 
VP35 [59] 
 Dose dependent protection 
(0-60%) with IV piperazine-
enriched PMOs targeting 
VP24 and VP35  
Reduced viremia and 
release of IL-6 and MCP-1 
with PMOs targeting VP24 
and VP35 
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Table 3. Cont. 
Peri- exposure Treatment  Dose and Route of 
Administration 
Mouse Model  Guinea Pig Model  NHP Model 
Antiviral Agents 
Antisense PMOs 
(continued) 
 
NHPs: 
 SC, IP, and IM of PMO(s) 
targeting VP35 or 
VP24,VP35, or L -2 days to 
through +9 days [58] 
 SC and IP of piperazine-
enriched PMOs 40 mg/kg 
targeting VP24 and VP35 
+30–60 minutes then daily 
for +10 or 14 days [59] 
 IV 4, 16, 28, or 40 mg/kg of 
piperazine-enriched PMOs 
targeting VP24 and VP35 
+30–60 minutes then daily 
for +14 days 
     100 times lower viral titers 
in treated NHPs than in 
NHPs receiving control 
PMOs targeted to MARV 
proteins 
AAbbreviations:  EBOV:  Zaire  ebolavirus  species;  GP:  glycoprotein;  Ig:  immunoglobulin;  IL-6:  interleukin-6;  IM:  intramuscular;  IP:  intraperitoneal;  IV:  intravenous;  
L:  L  polymerase;  mAb:  monoclonal  antibody;  MCP-1:  monocyte  chemotactic  protein-1;  NHP:  nonhuman  primate;  PFU:  plaque-forming  units;  PMO:  antisense 
phosphorodiamidate morpholino oligomers; RNA: ribonucleic acid; SC: subcutaneous; VP: viral protein; VSV: vesicular stomatitis virus 
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4. History of Outbred Strains of Syrian Hamster in U.S. 
Syrian  hamsters  (Mesocricetus  auratus)  are  used  in  research  studies  of  infectious  diseases  and 
cancer. In particular, Syrian hamsters are recognized as valuable animal models for studying emerging, 
acute  human  viral  diseases  caused  by  highly  pathogenic  RNA  viruses.  Outbred  strains  of  Syrian 
hamsters in the U.S. are currently available from 3 sources: Simonsen Laboratories, Charles River 
Laboratories, and Harlan Laboratories. Most or all of these sources obtained Syrian hamster stock  
from Jerusalem. In 1930, lengthy experiments on leishmaniasis at the Hebrew University of Jerusalem 
were hampered by limitations of the only animal model known for the disease, the Chinese hamster 
(Cricetus griseus) [61]. Continuous replenishment of Chinese hamster stocks from China was needed 
as conditions for successful breeding of captive Chinese hamsters were not known, and such hamsters 
succumbed to a Pasturella epidemic in the region. Instead, an endemic species of hamster, the Syrian 
or  golden  hamster  was  substituted  for  the  Chinese  hamster.  Syrian  hamsters  are  easily  bred  in 
captivity, relatively free from natural hamster diseases, but are susceptible to experimental pathogens 
and have a short life cycle [61,62]. With the success of the domesticated Syrian hamster as a model for 
leishmaniasis, tuberculosis, and brucellosis, Jerusalem scientists sent shipments of Syrian hamsters to 
U.S. research institutions (Western Reserve University, Rockefeller Foundation, U.S. Public Health 
Service) in 1938 and 1942. Leishmaniasis-infected hamsters were sent to the military during World 
War  II  (probably  not  bred)  for  evaluation  of  therapeutic  interventions  [61].  U.S.  research  studies 
utilizing the Syrian stocks originally from Jerusalem were first published the 1940s [63]. In the mid 
1940’s,  Albert  F.  Marsh  obtained  stock  probably  from  U.S.  Public  Health  Service  to  found  Gulf 
Hamstery [63,64]. Simonsen Laboratories acquired stock originating with Gulf Hamstery in 1962 and 
interbred  their  hamsters  with  stock  from  ARS/Sprague  Dawley  in  1978  [65].  In  1983,  Simonsen 
Laboratories derived the Sim: BR golden strain that is still commercially available. Similarly, Engle 
Laboratory Animals and Lakeview Hamstery purchased stock from Gulf Hamstery in 1949 [63,64]. 
Lakeview  Hamstery  became  a  subsidiary  of  Charles  River  in  1969,  and  stock  (Crl:  LVG)  is  still 
available today [66,67]. Engle Laboratory Animals was acquired by Harlan Laboratories in 1984, and 
the hamster stock originally from Engle Laboratory Animals is no longer commercially available [64]. 
Syrian hamster stock from ARS/Sprague Dawley was sent to Central Institute for Laboratory Breeding 
in  Hanover,  Germany  (HAN:  AURA)  in  1973  [68,69].  Harlan  Laboratories  purchased  the  Central 
Institute for Laboratory Breeding in 1994, and stock (HsdHan: AURA) is currently available.  
Currently available inbred strains of Syrian hamsters include Bio 1.5, Bio 14.6, Bio 15.16, Bio F1B, 
Bio HT, and Bio To-2 [70]. These strains are used as disease models for carcinogenicity, dental caries, 
cardiomyopathy, muscular dystrophy, diabetes, atherosclerosis, and hypertension. 
5. Syrian Hamsters as a Model of Viral Hemorrhagic Fever Diseases  
Approximately 145,895 hamsters were used in research in 2010 in the U.S. comprising 13% of total 
animal usage [71]. Although hamsters are still widely used, the number of hamsters currently used in 
research is well below peak usage of over 500,000 in the 1980s [72]. However, the total number of 
papers published from 1971 to 2011 has steadily increased (Figure 1) with the greatest increase in 
studies of viral infections. Availability, size, ease of care and breeding in laboratory conditions, and Viruses 2012, 4                                       
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cost contribute to the popularity of Syrian hamster as an alternative to nonhuman primates for  
viral research. 
Figure  1.  Number  of  publications  utilizing  hamsters  between  1971  through  2011.  
An  increase  in  use  of  hamsters  as  an  animal  model  for  parasitic,  bacterial,  and  viral 
diseases  is  noted in the  literature. During the 10-year period of 2001-2011, the  largest 
increase in publications was observed, the majority of which were in the virology sector.  
 
Hamsters are valuable animal models for studying viral hemorrhagic fevers, including EVD [27], 
Marburg virus disease [73], hantavirus cardio-pulmonary syndrome [74–79], arenavirus hemorrhagic 
fevers [80], yellow fever hemorrhagic  fever  [80–82], and phlebovirus  models of  Rift Valley  fever 
(Table 4) [83]. All of these viruses cause hemorrhagic fevers in hamsters, but infections caused by 
some  of  these  viruses  (e.g.,  Pirital,  Maporal)  that  serve  as  disease  models  (e.g.,  hantavirus 
cardiopulmonary syndrome, Lassa fever) are not pathogenic in humans [78,84]. A number of these 
viruses  were  hamster  adapted  (Marburg,  yellow  fever,  Pichinde)  [73,80,81,85]  or  mouse  adapted 
(Ebola) [27]. 
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Table 4. Hamsters as a model for viral hemorrhagic fevers. 
Pathology and laboratory abnormalities  Virus 
Spleen 
  Necrosis of white and red pulp, lymphoid zone 
 
 
Punta Toro [83] 
Pirital [84,86,87] 
Marburg [73] 
  Mild lymphoid depletion of white pulp, early infection  Ebola [27] 
  Lymphoid necrosis and reactive hyperplasia  Gabek Fores t[83] 
Yellow fever [81,82,85] 
  Destruction of tissue architecture, terminal phase  Ebola [27] 
  Mononuclear infiltrate expanding red pulp and obscuring  
lymphoid architecture 
Andes [75] 
  Proliferation of reticuloendothelial tissue, macrophages in sinuses  Marburg [73] 
  Apoptosis of mononuclear phagocytic system and lymphocytes,  
terminal phase 
Ebola [27] 
Liver 
  Hepatocellular necrosis  Punta Toro [83] 
  Hepatocellular necrosis, hemorrhage and fibrin deposition, inflammation  Ebola [27] 
  Hepatocelullar necrosis, mild steatosis  Gabek Forest [83] 
  Lobular microvesicular steatosis, monocytic infiltration, necrosis  Yellow fever [81,82,85] 
  Apoptosis/necrosis with inflammatory infiltration  Pirital [84,86,87] 
Andes [75,76,79] 
  Interstitial mononuclear infiltration  Maporal [78] 
  Increased AST  Yellow Fever [81,85] 
Pirital [84,86] 
  Increased total bilirubin  Yellow Fever [81] 
  Increased ALT  Punta Toro [83] 
Gabek Forest [83] 
Yellow Fever [81,85] 
Pichinde [80] 
Pirital [84,86] 
Lymph nodes 
  Lymphoid necrosis and reactive hyperplasia  Punta Toro [83] 
  Lymphoid necrosis and reactive hyperplasia, late infection  Ebola [27] 
  Lymphoid depletion and sinus hemorrhage, terminal phase  Ebola [27] 
  Follicular and plasma cell hyperplasia  Andes [76] 
  Proliferation of reticuloendothelial tissue, macrophages in sinuses  Marburg [73] 
  Histiocytosis and neutrophilia, early infection  Ebola [27] 
  Apoptosis of macrophages, dendritic cells, late infection  Ebola [27] 
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Table 4. Cont. 
Pathology and laboratory abnormalities  Virus 
Lung 
  Alveolar hemorrhage with histiocytic infiltration  Yellow fever[81]  
  Alveolar edema, fibrin deposition, pleural effusion  Andes[75,79] 
Maporal [78] 
  Interstitial pneumonitis, diffuse or focal atelectasis, hemorrhagic necrosis  Punta Toro [83] 
Pirital [87] 
  Interstitial pneumonitis, hemorrhage  Gabek Fores [83] 
Pirital [84,86] 
Andes [76] 
  Interstitial pneumonitis, proliferation of vascular endothelium, capillary 
congestion, fibrin deposition 
Marburg [73] 
Kidney 
  Tubular necrosis  Yellow Fever [82,85] 
  Tubular epithelium degeneration, mononuclear cell infiltration, 
intracytoplasmic bodies, thickening of Bowman’s capsule, shrinkage of 
glomerular tufts 
Marburg [73] 
  Glomerular necrosis  Gabek Forest [83] 
  Interstitial nephritis  Maporal [78] 
  Increased creatinine, blood urea nitrogen concentrations  Pirital [84,86] 
Vascular dysregulation 
  Vascular leakage (edema, effusion)  Andes [75,79] 
Pichinde [80] 
Yellow fever [80] 
Maporal [78] 
  Decreased albumin concentrations  Pichinde [80] 
Yellow fever [81] 
Pirital [86] 
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Table 4. Cont. 
Pathology and laboratory abnormalities  Virus 
Coagulopathy 
  Increased PT, aPTT 
 
Yellow Fever [81] 
Pirital [84,86] 
Andes [76] 
Ebola [27]  
  Increased TT  Pirital [86] 
Ebola [27] 
  Early increased, then decreased fibrinogen concentrations 
  Decreased fibrinogen concentrations, late infection 
  Increased fibrinogen concentration 
Yellow fever [81] 
Ebola [27]  
Andes [76] 
Pirital [84] 
  Increased D-dimer concentrations  Pirital [84] 
  Decreased protein C concentrations  Ebola [27] 
  Decreased protein S concentrations, late infection  Andes [76] 
  Thrombocytosis, mid or late infection  Pirital [84,86]  
  Thrombocytopenia, late infection  Andes [75] 
Yellow fever [81]  
Hematological abnormalities 
  Early leukopenia then leukocytosis (primarily neutrophils)   Yellow fever [81] 
  Leukocytosis mid-to-late infection  Pichinde [80] 
Pirital [86] 
Andes [75] 
  Lymphopenia  Andes [75] 
Cytokines 
  Increased blood cytokine concentrations, cross reactive mice antibodies  Pichinde [80] 
Andes [76] 
  Increased gene expression of cytokines  Andes [76] 
Yellow fever [85] 
Ebola [27] 
Viral  hemorrhagic  fever  is  a  syndrome  characterized  by  fever,  malaise,  increased  vascular 
permeability, and coagulation abnormalities that may lead to hemorrhage [80,88]. A number of factors 
contribute to alterations in vascular function such as  direct cytolytic infection of the endothelium, 
changes in tight junctions between endothelial cells, alterations in coagulation pathways, disruption of 
hematopoiesis,  and/or  the  release  of  cytokines  and  other  permeability  factors  (e.g.,  tissue  factor,  
TNF-α, nitric oxide) from endothelial cells, neutrophils, macrophages, and/or monocytes [1,80,89–92]. 
Although EBOV does infect endothelial cells of NHPs, infection occurs late in the disease course after 
the  development  of  disseminated  intravascular  coagulation  [89].  Rather,  researchers  consider  the 
release of cytokines and other vasoactive mediators to disrupt the endothelial barrier, causing plasma 
volume loss, hypovolemic shock, multi-organ failure, and death [93]. Impairment of liver function may Viruses 2012, 4                                       
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alter the production of vitamin K-associated coagulation factors (e.g., factor VII) and coagulation 
inhibitors (e.g., protein C) that could contribute to coagulopathy [26,27,92]. Thrombocytopenia occurs 
in part due to consumptive coagulopathy, but evidence from bone marrow aspirates in EBOV-infected 
nonhuman primates also reveals damaged megakaryocytes and atypical platelets [91].  
Among the Syrian hamster models of viral hemorrhagic fevers, liver and lungs are the commonly 
affected organs. Signs of tachycardia and tachypnea and results of hematological, blood chemistry, and 
coagulation tests indicative of vascular leakage or shock are noted in Syrian hamsters infected with 
Andes virus, [77] Pichindé or Pirital viruses, [80,84,86] or yellow fever virus [80]. Upregulation of 
cytokines in one study of hamsters challenged with Pichindé virus preceded vascular leakage [80].  
The search for an animal model that more closely resembles human EVD than other rodent models to 
date led to the development of the Syrian hamster model. 
6. Syrian Hamsters as an Ebola Virus Disease Model  
Data from a study of Syrian hamsters challenged IP or SC with MA-EBOV or wild-type EBOV 
indicate that only MA-EBOV given IP causes EVD reminiscent of human disease including, severe 
coagulopathy,  lymphocyte apoptosis, cytokine dysregulation (e.g., suppression of early type  I IFN 
responses), target organ necrosis and/or apoptosis (i.e., lymph nodes, spleen, liver), and lethal outcome 
(Tables 5–6) (Figure 2) [27]. Such suppression/non-induction of type-I IFN response and aberrant  
pro-inflammatory responses are suggested as some of the key pathogenic processes that lead to lethal 
outcome [20,27]. In contrast to MA-EBOV challenge, wild-type EBOV given IP in hamsters causes 
activation of early type-I IFN responses, mild inflammatory responses, induction of less-prominent 
apoptosis, and minimal pathological changes [27]. 
Table 5. Comparison of current animal models of Ebola virus disease. 
 
Macaque  Guinea pig  Hamster  Mouse 
Hallmarks of Human Disease 
Target cells/organs  +  +  +  + 
Cytokine dysregulation  +  ND 
a  +  +/-
 
Lymphocyte apoptosis  +  ND 
a  +  + 
Coagulation dysfunction  ++  +  ++  +/- 
Advantages/Disadvantages 
Availability  -  +/-  +  + 
Ease of handling  -  +/-  +  + 
Research reagents  ++  -  +/++  +++ 
Pathogenicity of MA-EBOV  ++ [20] 
b  +  +++  +++ 
a: ND = no data 
b: MA-EBOV = mouse-adapted EBOV 
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Table  6.  Comparison  of  pathological  changes  in  different  animal  models  of  Ebola  
virus disease. 
 
Liver  Spleen 
Hepatocellular 
degeneration 
and necrosis 
Inflammation  Fibrin 
Lymphoid 
necrosis and 
loss 
Inflammation  Fibrin 
Mouse  Diffuse, random  Neutrophilic  Little 
Multifocal, 
mild 
Neutrophilic  Little 
Guinea pig  Diffuse, random 
Neutrophilic and 
histiocytic 
Little to 
moderate 
Diffuse, 
severe 
Neutrophilic 
Little to 
moderate 
Hamster 
Diffuse, 
midzonal 
Neutrophilic  Little 
Diffuse, 
moderate to 
severe 
Neutrophilic  Little 
NHP  Diffuse, random  Neutrophilic  Abundant 
Diffuse, 
severe 
Neutrophilic  Abundant 
Figure 2. Temporal progression of disease in the Syrian hamster model of Ebola virus 
disease. Following exposure to 1000 focus-forming units of MA-EBOV IP, hamsters begin 
showing signs of illness around day 3. Changes in the innate immune response, coagulation 
parameters, and pathology are observed as early as days 1 and 2.  
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Figure 3. Comparison of pathology in mouse, guinea pig, hamster, and nonhuman primate. 
A Balb/c mouse and a Syrian hamster were infected IP with MA-EBOV; a Hartley strain of 
guinea pig was infected with GPA-EBOV; and a macaque was infected with wild-type 
EBOV.  (A-D)  Pathological  changes  in  liver  of  different  animal  models.  (A)  Mouse: 
Multifocal,  random  hepatocellular  degeneration  and  necrosis  (10x  and  40x  inset).  
(B) Guinea pig: Diffuse, random hepatocellular degeneration and necrosis. Inflammatory 
cells are nearly absent (10x and 40x inset). (C–D) Hamsters: Liver. (C) Diffuse, midzonal 
hepatocellular degeneration, necrosis, and congestion. Inflammatory cells are nearly absent 
(10x). Solid arrow: prominent intracytoplasmic filovirus inclusion bodies in hepatocytes 
(40x).  (D)  Diffuse,  random  hepatocellular  degeneration  and  necrosis  (10x).  Solid  star: 
fibrin  deposition  (40x  inset).  (E-L)  Pathological  changes  in  spleen  of  different  animal 
models. (E and I) Mouse: White and red pulp. White pulp (E); diffuse lymphoid necrosis 
and  loss (10x and 40x  inset). Red pulp (I);  mild to moderate acute splenitis and small 
amounts of fibrin (solid star) (40x). (F and J) Guinea pig: White and red pulp. White pulp 
(F); multifocal lymphoid necrosis (10x and 40x inset). Red pulp (J); multifocal, mild to 
moderate acute splenitis with necrosis. Solid star: small amounts of fibrin at marginal zone 
(40x). (G and K) Hamster: White and red pulp. White pulp (G); diffuse lymphoid necrosis 
(10x  and  40x  inset).  Red  pulp  (K);  mild  to  moderate  acute  splenitis  with  monocytic 
degeneration  and  necrosis  (40x).  (H  and  L)  NHP:  White  and  red  pulp.  
White pulp (H); diffuse  lymphoid  necrosis (10x and 20x  inset). Red pulp (L); diffuse, 
moderate acute splenitis (40x). Solid star: fibrin. 
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Figure 3. Cont.  
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The severity of coagulopathy observed in Syrian hamsters infected with MA-EBOV is similar 
to  that  observed  in  rhesus  macaques  following  challenge  with  wild-type  EBOV  (Table  1).  
Hepatic  changes  in  Syrian  hamsters  closely  resemble  those  of  rhesus  macaques,  including 
disseminated  hepatocellular  degeneration  and  necrosis  with  infiltration  of  moderate  numbers  of 
neutrophils and fewer macrophages than neutrophils (Table 6). In contrast to macaques, little fibrin 
deposition  occurs  within  hepatic  sinusoids  of  hamsters  (Figure  3).  Likewise,  splenic  lesions  in 
hamsters  are  also  similar  to  those  observed  in  macaques  and  are  characterized  by  necrosis  of 
lymphocytes and marked loss of white pulp. Additionally, multifocal acute splenitis is characterized by 
moderate  numbers  of  viable  and  degenerate  neutrophils  and  fewer  macrophages  than  neutrophils 
mixed with necrotic debris within the red pulp. Lymph nodes also display diffuse lymphoid necrosis 
and  loss  along  with  acute  lymphadenitis  and  draining  hemorrhage  (Figure  3).  In  terminal  Syrian 
hamsters, all cytokines tested (IL-1β, IL-2, IL-4, IL-6, and IL-12p35; tumor growth factor [TGF]-β; 
IFN-γ  induced protein [IP]-10 and IFN-γ; TNF-α) are upregulated  in the spleen,  liver, and blood, 
indicating potentially uncontrolled immune responses.  
7. Reagent and Assay Development 
Until recently, lack of available reagents and specific assays to monitor host responses in hamsters 
(including  early  innate  immune  responses)  limited  investigators to  studies  on  disease  progression, 
humoral immune responses, and pathology. The lack of a complete genome sequence of the Syrian 
hamster has retarded the development of molecular, genetic, and antibody-based assays. In lieu of a 
complete  genome,  a  number  of  studies  evaluated  the  cross  reactivity  of  antibody-based  (ELISA, 
Luminex
®)  assays  developed  for  other  rodents  against  Syrian  hamster  cytokines,  chemokines, 
adherins, growth factors, and other serum factors (Table 7) [76,80,94]. Data from most of these studies 
indicate  limited  cross  reactivity  of  Syrian  hamster  proteins  to  other  rodent  antibodies.  
However, monoclonal antibodies from rats, mice, goats, and rabbits specific for hamsters successfully 
identified hamster surface markers of immune cells (T cells, B cells, dendritic cells, macrophages) via 
flow  cytometry  [74,95–97].  Microarray  proteome  expression  studies  have  quantified  hamster 
responses to disease through cross species hybridization of Syrian hamster RNA to cDNA from other 
species (e.g., rat, mouse, human) [98–102]. The complete transcriptome of the Syrian hamster has been 
determined but is not yet publicly available, and a microarray chip is currently under development.  
As hamster-specific antibodies have not been made against cytokines/chemokines, gene expression of 
these factors during infection is tracked through quantitative reverse transcriptase polymerase chain 
reaction (qRT-PCR) [103–109]. Recently, use of qRT-PCR has been extended to include 51 registered 
hamster gene sequences targeting apoptosis, cell junction integrity, cell proliferation, and coagulation 
in addition to immunological responses [94]. qRT-PCR assays were utilized to profile host responses 
in  hamsters  infected  with  yellow  fever  virus,  Andes  virus,  and  EBOV  [27,85,94,109].  Use  of  
qRT-PCR assays will also contribute to identification of host response factors needed for survival in 
animals  treated  with  antiviral  drugs  and  of  protective  immune  response  in  vaccinated  animals.  
Such assays will be used until the full genome sequence is available for the development of large  
scale microarrays. 
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Table 7. Cross-reactive or hamster-specific reagents. 
Cross-reactive antibodies  
Mouse anti-mouse/rat MHC II [74]     Rat anti-mouse CD4 [74,96,97] 
Mouse anti-mouse Thy1.2 [74]  
Mouse anti-rat CD8, CD8β [74,97] 
   
Mouse, rabbit, and goat anti-hamster antibodies 
Mouse dendritic cell marker [95]  
Mouse pan lymphocyte [95] 
Mouse T cell [95] 
Mouse B cell [95] 
Mouse CD45 [95]  
  Mouse CD18 [95] 
Mouse MHC II [95] 
Rabbit IgG [95] 
Rabbit IgM [74]  
Goat IgG [74,78,96,97]  
Cross-reactive cytokine, chemokine, and serum factor assays  
Rat GM-CSF [94]    Mouse / Rat VCAM-1 [76,80]  
Rat Leptin [94]     Mouse / Rat vWF [80]  
Rat GRO/KC [94]     Mouse / Rat VEGF [80] 
Rat / Mouse IL-1α [80,94]     Mouse / Rat MDC [80]  
Mouse MIG [94]     Mouse / Rat SCF [80] 
Mouse IL-13 [94]     Mouse GCP-2 [80] 
Mouse / Rat IP-10 [76,80]    Mouse MCP-3 [80] 
Mouse /Rat M-CSF [76,80]     Mouse MIP-2 [80] 
Mouse /Rat MCP-1 [76,80] 
Mouse Fibrinogen [80]  
  Mouse MIP-3β [80] 
Mouse AST [80] 
Cross-reactive microarray hybridization  
DNA Microarrays  
 Rat Genome [98,102] 
  Mouse genes [100,101] 
  MicroRNA Microarrays 
  Human [99] 
  Rat 
  Mouse 
8. Future Perspectives 
Although the predictive value of the hamster model for efficacy testing of vaccines and therapeutics 
remains to be shown, numerous research tools are now available that will facilitate the use of this 
animal  model  in  future research on Ebola virus pathogenesis. The newly developed  hamster EVD 
model  will  certainly  augment  and  perhaps  may  one  day  replace  mice  and  guinea  models  as  an 
alternative model for pathogenesis studies and efficacy testing. Hamsters infected with MA-EBOV 
currently exhibit EVD manifestations most similar to primates, particularly with respect to coagulation 
abnormalities. Of particular interest is employment of this hamster model to confirm the efficacy of 
drugs  used  in  NHPs  to  control  coagulopathy  (e.g.,  recombinant  activated  protein  C,  recombinant 
nematode anticoagulant protein c2).  
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